Alert detail

LCD L38779: MolDX: Minimal Residual Disease Testing for Cancer — Palmetto GBA

Policy ID: LCD-L38779Specialty: OncologyAdded: 9/12/2026Effective: December 26, 2021lcd
Low

What changed

MRD cancer testing coverage rules for Palmetto GBA SE states.

Who’s affected: Oncology billing teams · Effective: December 26, 2021

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 10 billing codes.

The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.